Medicine
Asclera 0.01 g/2 mL injection
Asclera 0.01 g/2 mL injection is a prescription medicine containing Polidocanol for intravenous use, marketed by Methapharm, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 30°C, (59°F to 86°F).
Key facts
- Active ingredient (INN)
- Polidocanol
- Brand
- Asclera
- Strength
- 0.01 g/2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 2 mL
- Marketing authorisation holder
- Methapharm
- Manufacturer
- Methapharm
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 30°C, (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C05BB02 Polidocanol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 June 2010
- Identifiers
- RxCUI 968173, 968177, 968181 +1DailyMed set ID bb1f342b-5352-4059-a0b2-e60fd652fd28NDC 67850-140Application NDA021201
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 mL in 1 ampule | 67850-140-05 | Methapharm | 1 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 March 2010 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Polidocanol
Clinical summary
Polidocanol is a sclerosing agent indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. MedsAcross supplies Polidocanol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PolidocanolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Asclera prescribing information (Methapharm) · U.S. National Library of Medicine, DailyMed
Need Asclera 0.01 g/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.